Literature DB >> 31285661

Assessing the impact of mailing self-sampling kits for human papillomavirus testing to unscreened non-responder women in Manitoba.

F Jalili1, C O'Conaill1, K Templeton1, R Lotocki1, G Fischer2, L Manning2, K Cormier2, K Decker3,4.   

Abstract

Background: CervixCheck, Manitoba's cervical cancer screening program, conducted a pilot study to assess whether screening participation could be improved in unscreened women by offering a mailed self-sampling kit for human papillomavirus (hpv) testing instead of a Pap test.
Methods: In a prospective cohort study design, a sample of unscreened women (n = 1052) who had been sent an invitation letter from CervixCheck in the past but who did not respond were randomized to either an intervention group or a control group. The intervention group received a mailed hpv self-sampling kit; the control group received no additional communication. Returned hpv self-sampling swabs were analyzed by a provincial laboratory. After 6 months, screening participation in the two study groups was compared using a logistic regression model adjusted for age and area of residence (urban or rural). Secondary outcomes included hpv positivity, specimen inadequacy, compliance with follow-up, and time to colposcopy.
Results: Screening participation was significantly higher in the intervention group than in the control group (n = 51, 9.6%, vs. n = 13, 2.5%; odds ratio: 4.7; 95% confidence interval: 2.56 to 8.77). Geographic area of residence (urban or rural) and age were not statistically significant. Conclusions: The study demonstrated that hpv self-sampling kits can enhance screening participation in unscreened non-responder women in the setting of an organized screening program. Next steps should include additional research to determine the best implementation strategy for hpv self-sampling in Manitoba.

Entities:  

Keywords:  Human papillomavirus; cancer screening; cervical cancer; dna tests

Year:  2019        PMID: 31285661      PMCID: PMC6588079          DOI: 10.3747/co.26.4575

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  11 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Evaluating the effectiveness of cervical cancer screening invitation letters.

Authors:  Kathleen M Decker; Donna Turner; Alain A Demers; Patricia J Martens; Pascal Lambert; Daniel Chateau
Journal:  J Womens Health (Larchmt)       Date:  2013-08       Impact factor: 2.681

Review 3.  Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis.

Authors:  C Sarai Racey; Diana R Withrow; Dionne Gesink
Journal:  Can J Public Health       Date:  2013-02-11

4.  Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Authors:  Gina Suzanne Ogilvie; Dirk van Niekerk; Mel Krajden; Laurie W Smith; Darrel Cook; Lovedeep Gondara; Kathy Ceballos; David Quinlan; Marette Lee; Ruth Elwood Martin; Laura Gentile; Stuart Peacock; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  JAMA       Date:  2018-07-03       Impact factor: 56.272

5.  Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study.

Authors:  J Waller; M Jackowska; L Marlow; J Wardle
Journal:  BJOG       Date:  2011-06-14       Impact factor: 6.531

6.  Randomized Intervention of Self-Collected Sampling for Human Papillomavirus Testing in Under-Screened Rural Women: Uptake of Screening and Acceptability.

Authors:  C Sarai Racey; Dionne C Gesink; Ann N Burchell; Suzanne Trivers; Tom Wong; Anu Rebbapragada
Journal:  J Womens Health (Larchmt)       Date:  2015-11-24       Impact factor: 2.681

7.  Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening.

Authors:  Ingrid Wikström; Harriet Stenvall; Erik Wilander
Journal:  Acta Obstet Gynecol Scand       Date:  2007       Impact factor: 3.636

8.  Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in First Nation women from Northwest Ontario, Canada: a pilot study.

Authors:  Ingeborg Zehbe; Helle Moeller; Alberto Severini; Bruce Weaver; Nicholas Escott; Crystal Bell; Sandra Crawford; Diane Bannon; Natalie Paavola
Journal:  BMJ Open       Date:  2011-02-26       Impact factor: 2.692

9.  HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial.

Authors:  A Szarewski; L Cadman; D Mesher; J Austin; L Ashdown-Barr; R Edwards; D Lyons; J Walker; J Christison; A Frater; J Waller
Journal:  Br J Cancer       Date:  2011-02-22       Impact factor: 7.640

10.  Effect of vaginal self-sampling on cervical cancer screening rates: a community-based study in Newfoundland.

Authors:  Pauline Duke; Marshall Godwin; Samuel Ratnam; Lesa Dawson; Daniel Fontaine; Adrian Lear; Martha Traverso-Yepez; Wendy Graham; Mohamad Ravalia; Gerry Mugford; Andrea Pike; Jacqueline Fortier; Mandy Peach
Journal:  BMC Womens Health       Date:  2015-06-10       Impact factor: 2.809

View more
  2 in total

1.  HPV sampling options for cervical cancer screening: preferences of urban-dwelling Canadians in a changing paradigm.

Authors:  G D Datta; M H Mayrand; S Qureshi; N Ferre; L Gauvin
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

2.  Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.

Authors:  Misuzu Fujita; Minobu Shimazu; Kengo Nagashima; Misae Suzuki; Ichiro Tauchi; Miwa Sakuma; Setsuko Yamamoto; Makio Shozu; Hideki Hanaoka; Nobuhide Tsuruoka; Tokuzo Kasai; Akira Hata
Journal:  BMJ Open       Date:  2022-02-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.